{"schema_version":"secwatch.filing_event.v1","accession":"0001447362-22-000010","form_type":"8-K","ticker":"CSTL","cik":"0001447362","company_name":"CASTLE BIOSCIENCES INC","filed_at":"2022-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.517453+00:00","generated_at":"2026-06-27T19:19:48.845582+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Castle Biosciences expects FY 2021 revenue to meet or exceed $89-93M guidance; test volumes up 55%","bullets":["FY2021 revenue expected at or above guided $89-93M; year-end cash ~$330M.","Total gene expression profile test reports delivered in 2021: 28,118 (+55% YoY).","DecisionDx-Melanoma reports up 25% YoY to 20,328 despite 11% drop in melanoma diagnoses vs pre-COVID.","DecisionDx-SCC reports grew to 3,510 in 2021 from 485 in 2020; Q4 2021: 1,265 (+196%).","myPath/DecisionDx DiffDx-Melanoma reports: 2,662 in 2021 vs 73 in 2020; Q4: 904 vs 73."],"urls":{"canonical":"https://secwatch.observer/filing/0001447362-22-000010","json":"https://secwatch.observer/filing/0001447362-22-000010.json","markdown":"https://secwatch.observer/filing/0001447362-22-000010.md","text":"https://secwatch.observer/filing/0001447362-22-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447362/000144736222000010/0001447362-22-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447362/000144736222000010/cstl-20220110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T19:19:48.845582+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}